[go: up one dir, main page]

PE119199A1 - Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica - Google Patents

Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica

Info

Publication number
PE119199A1
PE119199A1 PE1998000882A PE00088298A PE119199A1 PE 119199 A1 PE119199 A1 PE 119199A1 PE 1998000882 A PE1998000882 A PE 1998000882A PE 00088298 A PE00088298 A PE 00088298A PE 119199 A1 PE119199 A1 PE 119199A1
Authority
PE
Peru
Prior art keywords
rna
infection
chronic hepatitis
alpha
patients
Prior art date
Application number
PE1998000882A
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE119199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE119199A1 publication Critical patent/PE119199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE AL USO JUNTO O SEPARADO DE a)RIBAVIRINA UTILIZANDOSE 400-1200 mg/DIA; b)INTERFERON ALFA UTILIZANDOSE DE 2-10 MILLONES UI; PARA LA FABRICACION DE UNA COMPOSICION QUE PUEDE SER UTIL PARA TRATAR UNA INFECCION POR HEPATITIS C CRONICA Y ERRADICAR EL VHC-ARN DETECTABLE, O UNA CARGA VIRAL MAYOR DE 2 MILLONES POR MILILITRO DE SUERO, MEDIDA POR PRC CUANTITATIVA DEL VHC-ARN. EL INTERFERON ALFA ES DE PREFERENCIA INTERFERON ALFA-2a, INTERFERON ALFA 2-b, INTERFERON ALFA CONSENSUAL, UN PRODUCTO DE INTERFERON ALFA PURIFICADO, INTERFERON ALFA PEGILADO
PE1998000882A 1997-09-21 1998-09-16 Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica PE119199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22

Publications (1)

Publication Number Publication Date
PE119199A1 true PE119199A1 (es) 1999-12-01

Family

ID=27130070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000882A PE119199A1 (es) 1997-09-21 1998-09-16 Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica

Country Status (24)

Country Link
EP (3) EP0903148B1 (es)
JP (1) JPH11152231A (es)
KR (1) KR20010024188A (es)
CN (1) CN1250283C (es)
AR (1) AR013497A1 (es)
AT (2) ATE230999T1 (es)
AU (1) AU749924B2 (es)
BR (1) BR9812484A (es)
CA (1) CA2245938C (es)
CO (1) CO4970691A1 (es)
DE (2) DE69801970T2 (es)
DK (2) DK1136075T3 (es)
ES (2) ES2162393T3 (es)
HK (2) HK1016505A1 (es)
HU (1) HUP0100092A3 (es)
IL (1) IL134428A0 (es)
MY (1) MY117781A (es)
NO (1) NO20001437D0 (es)
NZ (1) NZ502740A (es)
PE (1) PE119199A1 (es)
PT (1) PT903148E (es)
SK (1) SK3922000A3 (es)
TW (1) TW568787B (es)
WO (1) WO1999015194A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300540B6 (cs) * 1998-05-15 2009-06-10 Schering Corporation Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU8988901A (en) 2000-09-18 2002-03-26 Applied Research Systems Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
PT2604620T (pt) 2003-05-30 2016-08-18 Gilead Pharmasset Llc Analogos de nucleósido fluorados modificados
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008279087A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
PE20141056A1 (es) 2011-09-16 2014-09-05 Gilead Pharmasset Llc Metodos para el tratamiento de vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX351816B (es) 2013-01-31 2017-10-30 Gilead Pharmasset Llc Formulacion de combinacion de dos compuestos antivirales.
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
AR013497A1 (es) 2000-12-27
AU749924B2 (en) 2002-07-04
EP0903148B1 (en) 2001-10-10
DK0903148T3 (da) 2001-12-17
CN1250283C (zh) 2006-04-12
CA2245938C (en) 2003-07-15
ES2162393T3 (es) 2001-12-16
HK1041440A1 (en) 2002-07-12
NO20001437L (no) 2000-03-20
NZ502740A (en) 2002-10-25
EP1136075A1 (en) 2001-09-26
ES2186660T3 (es) 2003-05-16
CA2245938A1 (en) 1999-03-21
IL134428A0 (en) 2001-04-30
DK1136075T3 (da) 2003-04-28
DE69801970T2 (de) 2002-06-13
HK1041440B (zh) 2003-09-05
WO1999015194A1 (en) 1999-04-01
DE69810822T2 (de) 2003-11-20
EP1317929A2 (en) 2003-06-11
EP1317929A3 (en) 2003-07-02
DE69810822D1 (de) 2003-02-20
SK3922000A3 (en) 2000-10-09
PT903148E (pt) 2002-02-28
MY117781A (en) 2004-08-30
JPH11152231A (ja) 1999-06-08
CN1271292A (zh) 2000-10-25
HUP0100092A2 (hu) 2001-05-28
EP0903148A3 (en) 1999-04-28
EP0903148A2 (en) 1999-03-24
BR9812484A (pt) 2000-09-19
NO20001437D0 (no) 2000-03-20
ATE206618T1 (de) 2001-10-15
CO4970691A1 (es) 2000-11-07
KR20010024188A (ko) 2001-03-26
TW568787B (en) 2004-01-01
HUP0100092A3 (en) 2002-03-28
HK1016505A1 (en) 1999-11-05
DE69801970D1 (de) 2001-11-15
ATE230999T1 (de) 2003-02-15
EP1136075B1 (en) 2003-01-15
AU9473798A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
NZ330784A (en) Modulation of th1/th2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
HUP0000137A2 (hu) Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
BR0108997A (pt) Terapia imune adjuvante para hiv
MD990258A (en) Method of treatment of the acute viral hepatitis B
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
AU5535498A (en) Treatment of HIV positive patients
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
Mascolini Protease inhibitor update: treatment combination strategies
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
Highleyman Twice-daily Indinavir dosing not recommended
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
AR023390A1 (es) Terapia para la leucemia mielocitica cronica
Simmons Dressing up your virus: a new outfit for HIV
Baker Advantages of HIV treatment with Hydrea (Hydroxyurea)

Legal Events

Date Code Title Description
FC Refusal